Advanced in Splenic Infarction

Dr. Jatin K. Desani

Hematology Oncology | Hematology | Oncology
Hackensack Meridian Health Medical Group - Specialty Care PC
3600 Route 66, Fl 3, 
Neptune, NJ 
Offers Telehealth
Advanced in Splenic Infarction
Hackensack Meridian Health Medical Group - Specialty Care PC
3600 Route 66, Fl 3, 
Neptune, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jatin Desani is a Hematologist Oncology specialist and a Hematologist in Neptune, New Jersey. Dr. Desani and is rated as an Advanced provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC).

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Ocean Medical Center
Jfk Medical Center
Southern Ocean Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
3600 Route 66, Fl 3, Neptune, NJ 07753
Other Locations
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
30 Prospect Ave, Suite 2, Hackensack, NJ 07601
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1944 Route 33, Suite 203, Neptune, NJ 07753
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1140 Route 72 W, Manahawkin, NJ 08050

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

2 Total Publications

Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients.
Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients.
Journal: BMC cancer
Published: May 30, 2017
Similar Doctors
Experienced in Splenic Infarction
Dr. Moshe C. Chasky
Hematology Oncology | Hematology | Oncology
Experienced in Splenic Infarction
Dr. Moshe C. Chasky
Hematology Oncology | Hematology | Oncology

Alliance Cancer Specialists

1203 Langhorne Newtown Rd, Suite 135, 
Langhorne, PA 
 (44.2 mi)
215-750-5050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Moshe Chasky is a Hematologist Oncology specialist and a Hematologist in Langhorne, Pennsylvania. Dr. Chasky and is rated as an Advanced provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Anal Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Pleuropulmonary Blastoma.

Experienced in Splenic Infarction
Dr. Michael J. Levitt
Hematology Oncology | Hematology | Oncology
Experienced in Splenic Infarction
Dr. Michael J. Levitt
Hematology Oncology | Hematology | Oncology

Hackensack Meridian Health Medical Group - Specialty Care PC

1945 Route 33, 
Neptune, NJ 
 (2.6 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Levitt is a Hematologist Oncology specialist and a Hematologist in Neptune, New Jersey. Dr. Levitt and is rated as a Distinguished provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy.

Experienced in Splenic Infarction
Dr. Alexander Bershadskiy
Hematology Oncology | Hematology | Oncology
Experienced in Splenic Infarction
Dr. Alexander Bershadskiy
Hematology Oncology | Hematology | Oncology

North Shore Health System Medical Faculty Group Practice Inc

256 Mason Ave, C, 
Staten Island, NY 
 (25.2 mi)
718-226-6400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexander Bershadskiy is a Hematologist Oncology specialist and a Hematologist in Staten Island, New York. Dr. Bershadskiy and is rated as a Distinguished provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), Lung Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Desani's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 55 Advanced Conditions
    View All 131 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile